Nutriband Inc. (NASDAQ:NTRB) Short Interest Down 24.4% in January

Nutriband Inc. (NASDAQ:NTRBGet Free Report) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 54,900 shares, a drop of 24.4% from the December 31st total of 72,600 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average daily volume of 153,100 shares, the days-to-cover ratio is presently 0.4 days.

Analyst Ratings Changes

Separately, Noble Financial assumed coverage on Nutriband in a research report on Wednesday, January 22nd. They set an “outperform” rating and a $13.00 price objective on the stock.

View Our Latest Stock Analysis on Nutriband

Nutriband Stock Up 4.9 %

NTRB stock traded up $0.39 during mid-day trading on Friday, reaching $8.29. The company had a trading volume of 110,336 shares, compared to its average volume of 449,503. The firm has a fifty day simple moving average of $4.96 and a 200 day simple moving average of $5.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.83 and a current ratio of 4.96. Nutriband has a fifty-two week low of $2.22 and a fifty-two week high of $11.78. The company has a market capitalization of $92.10 million, a price-to-earnings ratio of -11.68 and a beta of 0.99.

Nutriband (NASDAQ:NTRBGet Free Report) last posted its quarterly earnings results on Tuesday, December 3rd. The company reported ($0.12) EPS for the quarter. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%. Analysts forecast that Nutriband will post -0.6 earnings per share for the current fiscal year.

About Nutriband

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

Further Reading

Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.